- ►annals.org [PDF] HA Ghofrani, R Wiedemann, F Rose, H … - Annals of internal medicine, 2002 - Am Coll Physicians Patients: 30 patients with severe pulmonary arterial hypertension (n 16),
chronic thromboembolic pulmonary hypertension (n 13), or pulmonary hypertension
due to aplasia of the left pulmo- nary artery (n 1), all classified as New ... Cited by 424 - Related articles - BL Direct - All 14 versions
- ►ahajournals.org H Wilkens, A Guth, J Konig, N Forestier, B … - Circulation, 2001 - Am Heart Assoc Methods and Results— The short-term effects of 8.4 to 10.5 µg of aerosolized
iloprost, the phosphodiesterase type 5 inhibitor sildenafil, and the combination
thereof were compared in 5 patients with primary pulmonary hypertension. ... Cited by 364 - Related articles - BL Direct - All 11 versions
- ►ahajournals.org E Michelakis, W Tymchak, D Lien, L Webster, … - Circulation, 2002 - Am Heart Assoc Methods and Results— We studied 13 consecutive patients (mean±SEM, 44±2
years of age; 9 women) referred for consideration of heart-lung transplantation
or as a guide to medical therapy. All but one were functional class III or ... Cited by 429 - Related articles - BL Direct - All 13 versions
- ►onlinejacc.org HA Ghofrani, F Rose, RT Schermuly, H … - Journal of the American College of Cardiology, 2003 - Elsevier We sought to investigate the impact of adjunct sildenafil on exercise capacity
and hemodynamic parameters in patients with pulmonary arterial hypertension
(PAH) who fulfilled predefined criteria of deterioration despite ongoing ... Cited by 264 - Related articles - BL Direct - All 15 versions
HA Ghofrani, R Wiedemann, F Rose, RT … - The Lancet, 2002 - Elsevier Pulmonary vascular resistance index was reduced by nitric oxide (−21·9%, 95%
Cl −14·1 to −36·2), epoprostenol (−36·9%, −24·4 to −59·6), and
sildenafil (−32·5%, −10·2 to −54·1). However, ratio of pulmonary ... Cited by 436 - Related articles - All 7 versions
H Olschewski, G Simonneau, N Galie, T … - New England Journal of Medicine, 2002 - content.nejm.org Methods We compared repeated daily inhalations of 2.5 or 5.0 µg of iloprost
(six or nine times per day; median inhaled dose, 30 µg per day) with inhalation
of placebo. A total of 203 patients with selected forms of severe pulmonary ... Cited by 845 - Related articles - BL Direct - All 19 versions
- ►atsjournals.org HA Ghofrani, RT Schermuly, F Rose, R … - American journal of respiratory and critical care …, 2003 - Am Thoracic Soc Only a small percentage of patients with chronic thromboembolic pulmonary
hypertension are eligible for pulmonary thrombendarterectomy. We investigated
the effects of oral sildenafil on hemodynamics and exercise capacity in 12 ... Cited by 215 - Related articles - BL Direct - All 6 versions
JJ Lepore, A Maroo, NL Pereira, LC Ginns, … - The American journal of cardiology, 2002 - Elsevier Breathing low concentrations of nitric oxide (NO) produces selective pulmonary
vasodilatation and increases exercise capacity in patients with pulmonary
hypertension of various etiologies,[1 and 2] and an acute pulmonary ... Cited by 147 - Related articles - All 5 versions
- ►171.66.122.149 G Simonneau, RJ Barst, N Galie, R Naeije, S … - American journal of respiratory and critical care …, 2002 - 171.66.122.149 Pulmonary arterial hypertension is a life-threatening disease for which
continuous intravenous prostacyclin has proven to be effective. However, this
treatment requires a permanent central venous catheter with the associated ... Cited by 629 - Related articles - BL Direct - All 9 versions
- ►ersjournals.com MM Hoeper, C Faulenbach, H Golpon, J … - European Respiratory Journal, 2004 - Eur Respiratory Soc The 6MWD at baseline was 346±66 m and improved to 403±80 m 3 months after
introduction of bosentan treatment. However, this effect was not sustained and,
after an interval of 11±5 months, the walk distance had declined to ... Cited by 167 - Related articles - BL Direct - All 8 versions
